January 31st 2023
This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.
Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
November 9th 2022Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Read More
HCV Reinfection Rare Among Patients Receiving Opioid Agonist Therapy
August 24th 2022Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.
Read More